Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of “Buy” by Brokerages

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has received an average rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $17.00.

A number of brokerages recently issued reports on VYGR. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Citigroup initiated coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Leerink Partners began coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock.

Insider Activity

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. This represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in VYGR. China Universal Asset Management Co. Ltd. lifted its position in shares of Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after purchasing an additional 4,098 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Voyager Therapeutics in the second quarter valued at $85,000. Intech Investment Management LLC purchased a new stake in Voyager Therapeutics during the 3rd quarter worth about $74,000. Victory Capital Management Inc. boosted its position in shares of Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of Voyager Therapeutics in the 2nd quarter valued at about $128,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $5.73 on Tuesday. The firm has a 50 day simple moving average of $6.46 and a 200-day simple moving average of $7.05. The stock has a market cap of $313.01 million, a price-to-earnings ratio of 8.07 and a beta of 0.90. Voyager Therapeutics has a 1-year low of $5.19 and a 1-year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same period in the prior year, the business posted ($0.59) earnings per share. Equities analysts expect that Voyager Therapeutics will post -0.89 earnings per share for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.